A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the Cardiff experimental cancer medicine centre to establish the feasibility of combining the tyrosine kinase inhibitor, ponatinib with chemotherapy in patients with acute myeloid leukaemia with a flt3 mutation.

Trial Profile

A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the Cardiff experimental cancer medicine centre to establish the feasibility of combining the tyrosine kinase inhibitor, ponatinib with chemotherapy in patients with acute myeloid leukaemia with a flt3 mutation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2015

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms AML19 Pilot
  • Most Recent Events

    • 18 Jul 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 21 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top